New Genmab/Seagen drug will cost up to USD 120,000
Patients being treated for cervical cancer in the US will pay a considerable sum to be treated with Genmab and Seagen's newly approved drug Tivdak, which the two companies will market together in the country.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT AND DANIEL PEDERSEN
This week's FDA approval of cervical cancer drug Tivdak is a historic one for Genmab. Although the company does have other approved drugs on the market – Darzalex, Kesimpta and Tepezza – this marks the first time that the company will market one of its own drugs.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst: New Genmab approval shows portfolio potential
For subscribers
